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Abstract
Background: Endothelial-Mesenchymal-Transition (EndMT) plays an essential role in cardiovascular development, and
recently became an attractive therapeutic target based on evidence supporting its involvement in fibrosis and cancer.
Important questions that remain to be answered are related to the molecular mechanisms that control EndMT in
different organs and distinct pathological conditions. The lack of a detailed protocol for induction of EndMT and the
assumption that TGF-β isoforms play similar roles on different types of endothelial cells, limit progress in the field. The
aim of this study was to compare the induction of EndMT by TGF-β isoforms in endothelial cells of different sources,
and define a detailed protocol for EndMT assessment in vitro.
Results: We compared the dose-dependent effect of TGF-β isoforms, under normoxia and hypoxia, on the induction
of EndMT in human coronary and pulmonary artery endothelial cells. Our results suggest that endothelial cells undergo
spontaneous EndMT with time in culture under the conditions tested. The extent of EndMT induction by TGF-β was
dependent on the dose and endothelial cell type. Furthermore, the potential of TGF-β to induce EndMT was reduced
under hypoxia relative to normoxia.
Conclusions: Our work suggests that the response of endothelial cells to TGF-β is intrinsic to the dose, cell type and
environment. Optimization of induction conditions may be essential, as pathways triggering EndMT may vary during
development and pathological conditions. Therefore, caution is needed regarding indiscriminate use of TGF-β to
induce EndMT for mechanistic studies.
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Background
Endothelial-mesenchymal transition (EndMT) is a physio-
logical process characterized by loss of cell-cell adhesion
and cytoskeletal alterations, leading to changes in cell
morphology and acquisition of invasive and migratory
properties [1, 2]. During EndMT, the expression of the
endothelial markers vascular endothelial cadherin (VE-
cadherin), CD31 and von willebrand factor (vWF), has
been reported to be reduced, and followed by an increase
in the expression of the mesenchymal and smooth muscle
markers vimentin, fibronectin, fibroblast-specific protein-
1 (FSP-1), alpha-smooth muscle actin (α-SMA), SM22-α
and calponin [1, 2]. EndMT plays an essential role in
cardiovascular development [3], and has gained clinical
relevance after discovery of its participation in fibrotic dis-
eases of the kidney, heart and lung [4–9], and also during
cancer progression [10, 11].
Mechanistic studies have demonstrated the involve-
ment of different growth and pro-inflammatory factors
on the induction of EndMT, although a special role has
been assigned to members of the transforming growth
factor-β (TGF-β) family [12–15]. Progress in the field
has been limited by the lack of a detailed EndMT induc-
tion approach, the use of endothelial cells obtained from
different species and tissues, and indiscriminate use of
different isoforms TGF-β as potent inducers of EndMT
with variable doses and time frames. An important
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question to be addressed is if similar EndMT induction
mechanisms occur in different tissues, especially consid-
ering the diversity of endothelial cells in different organs
[16] and dose-dependent role of members of the TGF-β
family [17, 18]. The aim of the present work was to
evaluate the induction of EndMT using a detailed protocol
generated based on literature reports to test the effect of
different doses of TGF-β in two distinct endothelial cell
lines of human origin. In addition, we tested the effect of
hypoxia on the induction of EndMT, as ischemia is an im-
portant trigger of tissue fibrosis, and has been shown to
induce the expression of TGF-β [19–23].
Methods
Cells Line and Culture Conditions
Human coronary artery (HCAEC) and microvascular
pulmonary artery (HMPAEC) endothelial cells, isolated
from single donors, were purchased from Lonza and
maintained according to manufacturer’s instruction in
microvascular endothelial growth media (EGM-MV).
All cells were used between passages 5–8 maximum,
and maintained under 37 °C and 5 % CO2 humidified
atmosphere.
Induction of EndMT by TGF-β Treatment
Endothelial cells (2x105 total) were plated in 60 mm col-
lagen coated culture dishes in EGM-MV media. A day
later, the culture media was changed to remove un-
bound/dead cells. Two days after initial plating, cells
were harvested from one dish for protein analysis to de-
termine the baseline levels of endothelial and smooth
muscle markers prior to EndMT induction. All other
culture dishes were treated separately with different
doses (2 ng/mL, 5 ng/mL, and 10 ng/mL) of TGF-β1 or
TGF-β2 (R&D Systems) every day, for a total period of
5 days. TGF-β treatment was performed without media
change to avoid stimulation by other growth factors
present in the culture media. At the end of 5 days, cells
were harvested for protein analysis and compared to
baseline. Untreated cells harvested at the end of 5 days
were used as control.
Induction of EndMT by Hypoxia Exposure
Endothelial cells were plated and treated essentially as
described above for the TGF-β EndMT induction proto-
col. Two days after initial plating and collection of base-
line lysates, cells were randomly divided in two groups
and placed under hypoxia (1 % O2) and normoxia (room
air condition at 21 % O2). In both cases, cells were main-
tained for a total period of 5 days without media change,
except that they were also treated in parallel with TGF-
β1 and TGF-β2 to determine the combined effects of
hypoxia and TGF-β. At the end of 5 days, cells were har-
vested for protein analysis and compared to baseline.
Evaluation of EndMT Induction
Induction of EndMT was assessed by Western Blot Ana-
lysis. Prior to lysate collection, cell viability was deter-
mined by microscopy under bright field and cell debris
removed by 3 washes of monolayers with phosphate buf-
fer saline. Cell lysates were prepared in RIPA buffer and
protein concentration estimated using Bradford Assay
(Bio-Rad) for normalization and loading of equal
amounts of protein (30 μg total protein). SDS-PAGE and
Western blots were performed according to standard
procedures [24] using primary antibodies anti-CD31
(Cell Signaling Technology, #3528), anti-α-SMA (Sigma,
#A2547), SM22-α (Abcam, #ab14106). Correct protein
loading was confirmed by Ponceau Staining and probing
with endogenous control antibodies anti-α-Tubulin
(Santa Cruz, SC-58666) and anti-Gapdh (Cell Signaling,
#2118). The same blot was probed with different anti-
bodies without the need of stripping methods as proteins
of interest differed in size. Chemiluminescent signal was
detected using the ChemiDocTM XRS System and
densitometry analysis performed using Quantity One
software (Bio-Rad). The ratio between proteins of inter-
est (CD31, α-SMA and SM22-α), and endogenous con-
trol (α-Tubulin or Gapdh) was calculated for data
normalization. Graphs represent fold change calculated
based on normalized data.
Statistical Analysis
Results were analyzed for significance using One-Way
ANOVA with Sigma-Plot and GraphPad Prism Software,
followed by Holm-Sidak or Newman-Keuls multiple com-
parison post-tests. When applicable, ANOVA on Ranks
was performed. Experiments were repeated 3 times for
HCAECs and 4 times for HMPAECs. Differences between
means were considered significant when p ≤ 0.05. All data
are presented as means ± standard error.
Results
Effect of Culture Time on the Expression of Smooth
Muscle Markers in Endothelial Cells
The length of EndMT induction was variable among pro-
tocols described in the literature, without clear description
of frequency in culture media replacement [7, 12, 13, 25],
which can itself be a form of stress for any cell type.
Therefore, we decided to start this study by investigating
the expression of smooth muscle markers with time using
commercially available human coronary artery (HCAECs)
and microvascular pulmonary (HMPAECs) endothelial
cells cultured for 5 days without media change. Western
blot analysis showed that cultures of both cell types
expressed detectable levels of the smooth muscle markers
α-SMA and SM22-α as early as 2 days after plating (Fig. 1).
After 5 days in culture, HMPAECs showed a trend to-
wards increase in the expression of α-SMA and SM22-α
Pinto et al. Biological Procedures Online  (2016) 18:10 Page 2 of 8
by 1.98 ± 0.32 and 1.69 ± 0.30-fold, respectively, relative to
baseline levels (2 days after plating). In HCAECs this in-
crease was less pronounced for SM22-α (1.43 ± 0.31-fold)
or slightly reduced in the case of α-SMA (0.81 ± 0.06-fold)
(Fig. 1). Interestingly, the expression of the endothelial
marker CD31 was increased in HCAECs by 2.94 ± 1.03-
fold while it remained unchanged in HMPAECs (Fig. 1).
Despite these trends, data quantification did not show any
statistical significance (Fig. 1b).
Effect of TGF-β on the Expression of Smooth Muscle
Markers in Endothelial Cells
The involvement of TGF-β in EndMT has been widely
described in the literature [12–15]. Nevertheless, a
standard detailed protocol for its application as a potent
inducer of EndMT in vitro has not been established. We
tested the effect of different doses of TGF- β1 and TGF-
β2 on the expression of smooth muscle markers in
HMPAECs and HCAECs. We found that treatment of
HCAECs with both TGF-β1 and TGF-β2 induced the
expression of α-SMA and SM22-α (Fig. 2). Although all
doses of TGF-β1 and TGF-β2 tested induced α-SMA ex-
pression, the one with highest effect was 5 ng/ml, which
caused 3.23 ± 0.35 and 2.54 ± 0.32 -fold increase, respect-
ively. Similarly, the expression of SM22-α was increased
in HCAECs with all doses of TGF-β1 and TGF-β2 tested
in a trend similar to α-SMA, though reaching higher fold
changes at lower doses (3.97 ± 1.82 vs 2.43 ± 0.19 for
2 ng/ml TGF-β1, and 3.62 ± 0.76 vs 1.87 ± 0.16 for 2 ng/
ml TGF-β2). The expression of endothelial markers is
expected to decrease during transition. However, despite
induction of smooth muscle markers in HCAECs with
both types of TGF-β, only with 5 ng/ml TGF-β2 we
observed a trend towards decrease in the expression
of the endothelial marker CD31 to 0.59 ± 0.21-fold, al-
though this decrease was not statistically significant.
In HMPAECs only TGF-β1 showed a significant effect
on the induction of α-SMA expression (Fig. 3), differ-
ent from what we observed in HCAECs in which
both types of TGF-β had an effect (Fig. 2). From the three
TGF-β1 doses tested, 5 ng/ml and 10 ng/ml were the most
effective, increasing α-SMA expression by 1.94 ± 0.29 and
1.77 ± 0.17-fold relative to untreated control, respectively.
Interestingly, no significant changes were detected in the
expression of SM22-α, like we observed in HCAECs. Fur-
thermore, the degree of α-SMA induction in HCAECs
was higher than in HMPAECs, 3.23 ± 0.35 vs. 1.94 ± 0.29
after treatment with 5 ng/ml TGF-β1.
Effect of Hypoxia on the Expression of Smooth Muscle
Markers in Endothelial Cells
Hypoxia has been known as an important inducer of tis-
sue fibrosis in different pathological processes [23, 25–27],
and its involvement in EndMT has been reported [23].
We tested the effect of 1 % hypoxia alone or in combin-
ation with TGF-β on the induction of smooth muscle
markers relative to baseline (2 days after plating) and nor-
moxia control (5 days later) in HCAECs and HMPAECs.
In HCAECs, hypoxia exposure for 5 days caused a further
decrease in the expression of α-SMA relative to control
cells under normoxia from 0.81 ± 0.06- down to 0.47 ±
0.10-fold. Interestingly, the opposite was observed for
SM22-α, which expression was significantly induced in
HCAECs, relative to baseline, from 1.43 ± 0.31-fold in
normoxia control to 11.41 ± 4.89 in hypoxia (Fig. 4a and
b). When comparing both cell types, inverse changes were
observed in the expression of α-SMA, and while it de-
creased in HCAECs (Fig. 4a and b), in HMPAECs it was
increased up to 1.98 ± 0.32-fold (Fig. 5a and b). Induction
of SM22-α by hypoxia was significant only in HCAECs
(Fig. 4a and b). In HMPAECs, SM22-α expression was in-
duced with time in culture without additional effect by
-Tubulin
HCAECsHMPAECs





Fig. 1 Time-dependent Change in the Expression of Endothelial and Smooth Muscle Markers in HMPAECs and HCAECs. a Representative Western
blot image comparing changes in the expression of the endothelial marker CD31 and the smooth muscle markers α-SMA and SM22-α in
HMPAECs and HCAECs with time in culture. b Quantification of endothelial and smooth muscle markers expression by densitometry analysis of
western blots. Results were normalized to α-tubulin (loading control) and expressed as fold-change relative to baseline (day 5 versus day 2 after
plating). CD31 (HMPAECs, n = 4; HCAECs, n = 3, non-significant); α-SMA (n = 3, non-significant), SM22-α (n = 3, non-significant)
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Fig. 2 Effect of TGF-β on the Expression of Endothelial and Smooth Muscle Markers in HCAECs. a Representative Western blot images comparing
changes in the expression of the endothelial marker CD31 and the smooth muscle marker α-SMA and SM22-α in HCAECs after exposure to different
doses of TGF-β1 and TGF-β2. b Quantification of endothelial and smooth muscle marker expression by densitometry analysis of western blots. Results
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Fig. 3 Effect of TGF-β on the Expression of Endothelial and Smooth Muscle Markers in HMPAECs. a Representative Western blot images comparing
changes in the expression of the endothelial marker CD31 and the smooth muscle marker α-SMA and SM22-α in HMPAECs after exposure to different
doses of TGF-β1 and TGF-β2. b Quantification of endothelial and smooth muscle marker expression by densitometry analysis of western blots. Results
were normalized to α-Tubulin and Gapdh (loading control) and expressed as fold-change relative to control without TGF-β. (n = 3–4, *p < 0.05)
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hypoxia as observed in HCAECs. These results indicate
that in HMPAECs, the induction of smooth muscle
markers relative to baseline is independent of the oxygen
levels and the marker tested, but related to the length of
time in culture (Fig. 5a and b). Although the expression of
α-SMA and SM22-α in HCAECs was induced by both
TGF-β1 and TGF-β2 under normoxia, only TGF- β1 in-
duced a significant increase in the expression of α-SMA
under hypoxia of 1.75 ± 0.31-fold, without affecting the
expression of SM22-α (Fig. 4c). Similar results were found
for HMPAECs regarding the effect of TGF-β and α-SMA
expression, without changes in SM22-α (Fig. 5). The
endothelial marker CD31 was induced in both cell types
under hypoxia, probably due to hypoxia-induced inflam-
matory response (Figs. 4 and 5).
Discussion
The involvement and potential targeting of EndMT in fi-
brotic conditions has increased the research demand in
the field. Most studies have pursued the use of TGF-β as
the main tool for induction of EndMT based on its well-
known contribution to endocardial cushion formation
during development and fibrotic diseases [1, 26]. However,
the lack of a detailed protocol that could be reproduced
by the research community, the general assumption that
all members of the TGF-β family play similar roles on the
induction of EndMT, and that all endothelial cells respond
to extracellular signals the same way is not realistic. In the
present study, we investigated the effect of two members
of the TGF-β family on the induction of EndMT using
two different types of human adult endothelial cells.
In addition, we tested the effect of hypoxia on the in-
duction of EndMT, as ischemia is an important trig-
ger of tissue fibrosis [27].
One of the first problems we encountered when start-
ing our studies on EndMT was the lack of detailed and
consistent information regarding the culture conditions,
concentration and duration of TGF-β treatment. In
addition, TGF-β treatment ranged in general from 2 to
10 days in serum-free conditions or media supplemented
with serum [9, 12, 13, 28, 29]. Importantly, it was not
clear if the culture media was replaced along treatment
or if TGF-β was added without media change. These are
relevant information as serum-free conditions may in-
duce massive endothelial cell death as early as 24 h (per-
sonal unpublished observations), and different pathways
would be stimulated by culture media change, especially
if serum-supplemented. Based on these considerations
and findings from the literature, we designed a protocol
with commercially available HMPAECs and HCAECs
Normoxia Hypoxia























Fig. 4 Effect of Hypoxia and TGF-β on the Expression of Endothelial and Smooth Muscle Markers in HCAECs. a Representative Western blot images
comparing changes in the expression of the endothelial marker CD31 and the smooth muscle marker α-SMA and SM22-α in HCAECs after exposure to
different doses of TGF-β1 and TGF-β2 under Normoxia (21 % O2) and Hypoxia (1 % O2). b Quantification of endothelial and smooth muscle marker
expression by densitometry analysis of western blots comparing the effect of hypoxia to baseline and normoxia control. c Quantification of endothelial
and smooth muscle marker expression by densitometry analysis of western blots comparing the effect of TGF-β1 and TGF-β2 under Normoxia (21 %
O2) and Hypoxia (1 % O2). Results were normalized to α-Tubulin and Gapdh (loading control) and expressed as fold-change relative to baseline (BL) in
B, and relative to control without TGF-β in C. (n = 3, *p < 0.05, **p < 0.005)
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consisting of 5 days TGF-β treatment, without culture
media change, in which only TGF-β was added daily to
the culture. When reviewing the literature we found a
wide range in doses of different TGF-β isoforms tested,
with many studies tending to the use the high dose of
10 ng/ml. In addition, when TGF-β isoforms have been
tested together, the same dose has been used for the
different isoforms, assuming that they would act in a
similar fashion, compared to when tested alone. This
generates concern, especially in the case of TGF-β,
which has been reported to trigger different, sometimes
opposite, effects depending on the dose used [18]. Our
results show that low-to-intermediate doses of both
TGF-β1 and TGF-β2, below 10 ng/ml, are sufficient to
induce the expression of α-smooth muscle actin in both
HCAECs and HPAECs. These findings are supported by
reports showing that low concentrations ranging from
0.25–2 ng/ml were sufficient to induce EndMT [29–31].
One important feature of EndMT is loss of the endothe-
lial phenotype, characterized by decreased expression of
cell surface molecules. Interestingly, in our study, we
were not able to see a robust decrease in the expression
of the endothelial marker CD31, as previously reported.
In fact, we saw a high degree of variability in the expres-
sion of CD31. Similar observations have been reported
in aortic valve endothelial cells, which retained CD31 ex-
pression after TGF-β1 treatment [27], and further sup-
ported by another study showing that TGF-β caused
only a slight decrease in the expression of CD31 in pan-
creatic microvascular cells [8]. Changes in the expression
of endothelial markers may not occur all at once and
may also be specific to individual proteins. Kokudo et al
reported that although TGF-β2 treatment caused a
decrease in the expression of claudin-5, the expression
of VE-cadherin was unaffected, suggesting a marker-
specific effect [12]. It is possible that our findings indi-
cate an intermediate phenotype of EndMT, which has
partially undergone transition [32], as loss of the endo-
thelial phenotype during transition has been proposed to
occur after completion of EndMT [8].
Hypoxia has been shown to be a potent inducer of
epithelial-mesenchymal transition (EMT) in fibrotic dis-
ease [20, 33] and cancer [34], through mechanisms that
may involve activation of TGF-β signaling [20, 21]. Simi-
larly, the contribution of hypoxia to EndMT has also
been demonstrated [19, 23, 35, 36]. In the present study
we show different results regarding the expression of α-
smooth muscle actin after exposure to hypoxia. We
found that the expression of α-SMA in HMPAECs





















Fig. 5 Effect of TGF-β on the Expression of Endothelial and Smooth Muscle Markers in HMPAECs. a Representative Western blot images comparing
changes in the expression of the endothelial marker CD31 and the smooth muscle marker α-SMA and SM22-α in HMPAECs after exposure to different
doses of TGF-β1 and TGF-β2 under Normoxia (21 % O2) and Hypoxia (1 % O2). b Quantification of endothelial and smooth muscle marker expression
by densitometry analysis of western blots comparing the effect of hypoxia to baseline and normoxia control. c Quantification of endothelial and
smooth muscle marker expression by densitometry analysis of western blots comparing the effect of TGF-β1 and TGF-β2 under Normoxia (21 % O2)
and Hypoxia (1 % O2). Results were normalized to Gapdh (loading control) and expressed as fold-change relative to baseline (BL) in B, and relative to
control without TGF-β in C. (n = 3–4, *p < 0.05)
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normoxia, relative to baseline, similar to what was ob-
served under hypoxia. This result suggests that the in-
crease in the expression of these proteins was probably
related to the length of time they were maintained in
culture along the experiment. Coexpression of smooth
muscle markers in endothelial cells has been previously
described [14, 29, 31, 37]. Freshly purified bovine adult
arterial endothelial cells showed spontaneous and pro-
gressive increase in the expression of smooth muscle
markers with time in culture, triggered shortly after cell
isolation [31]. Paranya et al showed that certain clones
of endothelial cells undergo EndMT independent of
TGF-β treatment, when grown under low-serum condi-
tions [27]. We may speculate that in our case, by not
changing the culture media for a period of 5 days, nutri-
ents are depleted, mimicking low-serum condition.
Interestingly, in HCAECs exposed to hypoxia we found
that α-SMA expression was decreased relative to base-
line and normoxia control, different from recently pub-
lished findings showing a significant increase in the
expression of this marker after exposure to hypoxia [23].
The reason for these inverse findings on the expression
of α-SMA in HCAECs is not clear. We found that the
induction effect of TGF-β in HCAECs α-SMA expres-
sion is significantly reduced under hypoxia relative to
normoxia. These results suggest that mechanisms in-
volved in the control of TGF-β signaling under hypoxic
stress may play a role in α-SMA decreased expression.
One possibility is an additive effect of endogenous TGF-
β produced under hypoxia and the amount supple-
mented, reaching high inhibitory levels.
Conclusions
Optimization of EndMT induction conditions is critical,
as pathways triggering this process may vary during de-
velopment and pathological conditions. Our findings in-
dicate that the response of endothelial cells to TGF-β is
intrinsic to the dose, cell type and environment, suggest-
ing that special attention is needed to the current design
of EndMT studies and essential for reproducibility in
future studies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MTP designed, conducted the experiments, analyzed data and wrote the
manuscript. COR designed the experiments, analyzed data and wrote the
manuscript. DTC and SK contributed to experimental design and writing of
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by discretionary funds from the Interdisciplinary Stem
Cell Institute, University of Miami Miller School of Medicine, Miami, FL, to
Claudia O. Rodrigues. M.T.P. was a fellow of Fundação de Amparo à Pesquisa
do Estado de São Paulo (FAPESP), fellowship number 2011/21740-7. We would
like to thank Dr. Keith Webster for critical reading of this manuscript.
Author details
1Interdisciplinary Stem Cell Institute, University of Miami Leonard M. Miller
School of Medicine, Biomedical Research Building, 1501 NW 10th Avenue,
Room 826, Miami, FL 33136, USA. 2Instituto Nacional de Ciência e Tecnologia
em Células-Tronco e Terapia Celular e Fundação Hemocentro de Ribeirão
Preto, Ribeirão Preto, SP, Brazil. 3Faculdade de Ciências Farmacêuticas de
Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
4Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo,
Ribeirão Preto, SP, Brazil. 5Department of Molecular and Cellular
Pharmacology, University of Miami Leonard M. Miller School of Medicine,
Miami, FL 33136, USA.
Received: 14 March 2016 Accepted: 11 April 2016
References
1. Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in
development and pathological process. IUBMB Life. 2012;64(9):717–23.
2. Piera-Velazquez S, Jimenez SA. Molecular mechanisms of endothelial to
mesenchymal cell transition (EndoMT) in experimentally induced fibrotic
diseases. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S7.
3. Markwald RR, Fitzharris TP, Manasek FJ. Structural development of
endocardial cushions. Am J Anat. 1977;148(1):85–119.
4. He J, Xu Y, Koya D, Kanasaki K. Role of the endothelial-to-mesenchymal
transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. 2013;
17(4):488–97.
5. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in
kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc
Nephrol. 2008;19(12):2282–7.
6. Ghosh AK, Nagpal V, Covington JW, Michaels MA, Vaughan DE. Molecular
basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential
expression of microRNAs during EndMT. Cell Signal. 2012;24(5):1031–6.
7. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-
to-mesenchymal transition: potential contribution to vascular remodeling in
chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;
293(1):L1–8.
8. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T,
Shimokata K, Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-
induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010;43(2):161–72.
9. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E,
Chandraker A, Yuan X, Pu WT, Roberts AB, et al. Endothelial-to-mesenchymal
transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952–61.
10. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal
transition in cancer progression. Br J Cancer. 2008;99(9):1375–9.
11. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial
to mesenchymal transition as a source for carcinoma-associated fibroblasts.
Cancer Res. 2007;67(21):10123–8.
12. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail
is required for TGFbeta-induced endothelial-mesenchymal transition of
embryonic stem cell-derived endothelial cells. J Cell Sci. 2008;121(Pt 20):
3317–24.
13. Medici D, Potenta S, Kalluri R. Transforming growth factor-beta2 promotes
Snail-mediated endothelial-mesenchymal transition through convergence of
Smad-dependent and Smad-independent signalling. Biochem J. 2011;437(3):
515–20.
14. Mahler GJ, Farrar EJ, Butcher JT. Inflammatory cytokines promote
mesenchymal transformation in embryonic and adult valve endothelial cells.
Arterioscler Thromb Vasc Biol. 2013;33(1):121–30.
15. Arciniegas E, Sutton AB, Allen TD, Schor AM. Transforming growth factor
beta 1 promotes the differentiation of endothelial cells into smooth muscle-
like cells in vitro. J Cell Sci. 1992;103(Pt 2):521–9.
16. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS,
Wang Z, Rockson SG, van de Rijn M, Botstein D, et al. Endothelial cell
diversity revealed by global expression profiling. Proc Natl Acad Sci U S A.
2003;100(19):10623–8.
17. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P.
Balancing the activation state of the endothelium via two distinct TGF-beta
type I receptors. EMBO J. 2002;21(7):1743–53.
18. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-beta
family in vascular morphogenesis and disease. Trends Cell Biol. 2010;20(9):
556–67.
Pinto et al. Biological Procedures Online  (2016) 18:10 Page 7 of 8
19. Bijkerk R, de Bruin RG, van Solingen C, Duijs JM, Kobayashi K, van der Veer
EP, ten Dijke P, Rabelink TJ, Goumans MJ, van Zonneveld AJ. MicroRNA-155
functions as a negative regulator of RhoA signaling in TGF-beta-induced
endothelial to mesenchymal transition. Microrna. 2012;1(1):2–10.
20. Copple BL, Bustamante JJ, Welch TP, Kim ND, Moon JO. Hypoxia-inducible
factor-dependent production of profibrotic mediators by hypoxic
hepatocytes. Liver Int. 2009;29(7):1010–21.
21. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-
mesenchymal transition. Sci Signal. 2014;7(344):re8.
22. Goumans MJ, van Zonneveld AJ, ten Dijke P. Transforming growth factor
beta-induced endothelial-to-mesenchymal transition: a switch to cardiac
fibrosis? Trends Cardiovasc Med. 2008;18(8):293–8.
23. Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM. Snail Is a Direct
Target of Hypoxia-inducible Factor 1alpha (HIF1alpha) in Hypoxia-induced
Endothelial to Mesenchymal Transition of Human Coronary Endothelial
Cells. J Biol Chem. 2015;290(27):16653–64.
24. Florea V, Bhagavatula N, Simovic G, Macedo FY, Fock RA, Rodrigues CO. c-
Myc is essential to prevent endothelial pro-inflammatory senescent
phenotype. PLoS One. 2013;8(9):e73146.
25. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T.
Transforming growth factor-beta-induced endothelial-to-mesenchymal
transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol.
2012;32(2):361–9.
26. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal
transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol.
2011;179(3):1074–80.
27. Paranya G, Vineberg S, Dvorin E, Kaushal S, Roth SJ, Rabkin E, Schoen FJ,
Bischoff J. Aortic valve endothelial cells undergo transforming growth
factor-beta-mediated and non-transforming growth factor-beta-mediated
transdifferentiation in vitro. Am J Pathol. 2001;159(4):1335–43.
28. Diez M, Musri MM, Ferrer E, Barbera JA, Peinado VI. Endothelial progenitor
cells undergo an endothelial-to-mesenchymal transition-like process
mediated by TGFbetaRI. Cardiovasc Res. 2010;88(3):502–11.
29. Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA, Loukogeorgakis
S, Schoen FJ, Bischoff J. Human pulmonary valve progenitor cells exhibit
endothelial/mesenchymal plasticity in response to vascular endothelial
growth factor-A and transforming growth factor-beta2. Circ Res. 2006;99(8):
861–9.
30. Mihira H, Suzuki HI, Akatsu Y, Yoshimatsu Y, Igarashi T, Miyazono K, Watabe
T. TGF-beta-induced mesenchymal transition of MS-1 endothelial cells
requires Smad-dependent cooperative activation of Rho signals and MRTF-
A. J Biochem. 2012;151(2):145–56.
31. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise
to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in
vitro analysis. Circ Res. 2002;90(11):1189–96.
32. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest. 2009;119(6):1420–8.
33. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B,
Saito Y, Johnson RS, Kretzler M, Cohen CD, et al. Hypoxia promotes
fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal
transition. J Clin Invest. 2007;117(12):3810–20.
34. Shaikh D, Zhou Q, Chen T, Ibe JC, Raj JU, Zhou G. cAMP-dependent protein
kinase is essential for hypoxia-mediated epithelial-mesenchymal transition,
migration, and invasion in lung cancer cells. Cell Signal. 2012;24(12):2396–406.
35. Choi SH, Hong ZY, Nam JK, Lee HJ, Jang J, Yoo RJ, Lee YJ, Lee CY, Kim KH,
Park S, et al. A Hypoxia-Induced Vascular Endothelial-to-Mesenchymal
Transition in Development of Radiation-Induced Pulmonary Fibrosis. Clin
Cancer Res. 2015;21(16):3716–26.
36. Lee SW, Won JY, Kim WJ, Lee J, Kim KH, Youn SW, Kim JY, Lee EJ, Kim YJ,
Kim KW, et al. Snail as a potential target molecule in cardiac fibrosis:
paracrine action of endothelial cells on fibroblasts through snail and CTGF
axis. Mol Ther. 2013;21(9):1767–77.
37. Beranek JT. Vascular endothelium-derived cells containing smooth muscle
actin are present in restenosis. Lab Invest. 1995;72(6):771.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pinto et al. Biological Procedures Online  (2016) 18:10 Page 8 of 8
